민감성 피부 진단용 바이오 마커 및 이를 이용한 진단 키트
    51.
    发明公开
    민감성 피부 진단용 바이오 마커 및 이를 이용한 진단 키트 有权
    用于预测敏感性皮肤和测试套件的生物标记

    公开(公告)号:KR1020090123049A

    公开(公告)日:2009-12-02

    申请号:KR1020080048930

    申请日:2008-05-27

    CPC classification number: C12Q1/6883 C12Q2600/136

    Abstract: PURPOSE: A biomarker of which expression is specifically decreased or suppressed in the sensitive skin is provided to quickly diagnose sensitive skin and used for screening a relieving agent. CONSTITUTION: A biomarker for diagnosing sensitive skin contains gene of which expression is decreased or increased in the sensitive skin compared to healthy skin or a protein encoding the gene. A method for screening a relieving agent of sensitivity comprises: a step of conjugating a candidate agent to a protein encoded by a gene of which expression is increased or decreased in the sensitive skin; and a step of confirming the suppression of protein activity.

    Abstract translation: 目的:提供敏感皮肤中特异性降低或抑制表达的生物标志物,以快速诊断敏感皮肤并用于筛选缓解剂。 构成:与健康皮肤或编码该基因的蛋白质相比,用于诊断敏感皮肤的生物标志物含有敏感皮肤中表达降低或增加的基因。 用于筛选敏感性缓释剂的方法包括:将候选试剂与由敏感皮肤中表达增加或减少的基因编码的蛋白质缀合的步骤; 以及确认蛋白质活性抑制的步骤。

    수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
    52.
    发明授权

    公开(公告)号:KR100724586B1

    公开(公告)日:2007-06-04

    申请号:KR1020050120371

    申请日:2005-12-09

    Abstract: A pentaaza macrocycle metal complex is provided to show excellent active oxygen scavenging capability with less toxicity and side effect, thereby being used as a pharmaceutical composition for preventing or treating diseases related to the active oxygen such as skin aging, cancer, dementia, and rheumatoid. The pentaaza macrocycle metal complex is represented by the formula(I), wherein each R1, R2, R3 and R4 is independently H or C1-4 alkyl substituted by a hetero cycle or an aromatic cycle, the hetero cycle and the aromatic cycle able to be substituted by at least one substituent selected from the group consisting of C1-4 alkoxy, halogen, nitro, cyano, hydroxy, carboxyl and amino, each R5 and R6 is independently C1-7 alkyl or the R5 and R6 form a ring by being bound by C3-5 alkylene, M is a divalent metal selected from the group consisting of Mn, Fe and Cu, and each X and Y is independently a halide anion selected from the group consisting of Cl, Br, I, ClO3, ClO2, ClO, BrO4, BrO3, BrO2, BrO, IO4, and IO3, an anion of an organocarboxylic acid selected from the group consisting of acetic acid, trifluoroacetic acid, citric acid, formic acid, maleic acid, oxalic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid, methane sulfonic acid, benzene sulfonic acid and para-toluene sulfonic acid, an anion of a nitrate or a bicarbonate, and carboxylate or phenolate linked to one of the R1 to R6, provided that at least one of the R1, R2, R3 and R4 is not H. The pharmaceutical composition for preventing and treating cancer, stroke, Parkinson's disease, Alzheimer's disease, myocardial infarction, diabetic vascular disorder, hyperlipidemia, acute inflammation, rheumatoid, alcoholic hepatitis, glaucoma, macular degeneration and diabetic retinopathy comprises the pentaaza macrocycle metal complex as an effective ingredient.

    Abstract translation: 本发明提供五氮杂大环金属络合物,其显示优异的活性氧清除能力,毒性和副作用较小,因此可用作预防或治疗与皮肤老化,癌症,痴呆和类风湿等活性氧有关的疾病的药物组合物。 五氮杂大环金属配合物由式(I)表示,其中每个R 1,R 2,R 3和R 4独立地为H或被杂环或芳环取代的C 1-4烷基,杂环和芳环可以 被至少一个选自C 1-4烷氧基,卤素,硝基,氰基,羟基,羧基和氨基的取代基取代,每个R 5和R 6独立地为C 1-7烷基或者R 5和R 6通过 M是选自Mn,Fe和Cu的二价金属,并且每个X和Y独立地是选自Cl,Br,I,ClO 3,ClO 2, ClO,BrO 4,BrO 3,BrO 2,BrO,IO 4和IO 3,选自乙酸,三氟乙酸,柠檬酸,甲酸,马来酸,草酸,琥珀酸,苯甲酸的有机羧酸的阴离子 ,酒石酸,富马酸,扁桃酸,抗坏血酸,苹果酸,甲磺酸,b 苯磺酸和对甲苯磺酸,硝酸盐或碳酸氢盐的阴离子以及与R1-R6之一连接的羧酸盐或酚盐,条件是R1,R2,R3和R4中的至少一个不是H. 用于预防和治疗癌症,中风,帕金森病,阿尔茨海默氏病,心肌梗塞,糖尿病血管病症,高脂血症,急性炎症,类风湿,酒精性肝炎,青光眼,黄斑变性和糖尿病性视网膜病的药物组合物包含五氮杂大环金属络合物作为有效 成分。

    활성 산소 억제제
    54.
    发明公开
    활성 산소 억제제 失效
    反应性氧气物种抑制剂

    公开(公告)号:KR1020050048216A

    公开(公告)日:2005-05-24

    申请号:KR1020030082088

    申请日:2003-11-19

    CPC classification number: A61K33/32 A61K33/26

    Abstract: 본 발명은 수퍼옥사이드 디스뮤타제(superoxide dismutase; 이하 'SOD') 및 카탈라제(catalase) 활성을 가지는 화합물 및 이를 유효성분으로 포함하는 활성산소 억제제에 관한 것으로, 본 발명의 활성 산소 소거능이 뛰어나고 독성이나 부작용이 적은 SOD 및 카탈라제 유도체 화합물은 피부 노화, 암, 치매, 류마티스 등의 활성산소와 관련된 질병의 예방 또는 치료용 약제 조성물 등의 제조에 이용될 수 있다.

    활성 산소 억제제
    56.
    发明授权
    활성 산소 억제제 失效
    反应性氧气物种抑制剂

    公开(公告)号:KR100648618B1

    公开(公告)日:2006-11-23

    申请号:KR1020030082088

    申请日:2003-11-19

    Abstract: 본 발명은 수퍼옥사이드 디스뮤타제(superoxide dismutase; 이하 'SOD') 및 카탈라제(catalase) 활성을 가지는 화합물 및 이를 유효성분으로 포함하는 활성산소 억제제에 관한 것으로, 본 발명의 활성 산소 소거능이 뛰어나고 독성이나 부작용이 적은 SOD 및 카탈라제 유도체 화합물은 피부 노화, 암, 치매, 류마티스 등의 활성산소와 관련된 질병의 예방 또는 치료용 약제 조성물 등의 제조에 이용될 수 있다.
    활성 산소 억제제, 수퍼옥사이드 디스뮤타제(superoxide dismutase; 이하 'SOD'), 카탈라제(catalase)

Patent Agency Ranking